:@0.914624:0.081813:0.920519:0.081813:0.920519:0.063369:0.914624:0.063369:0.005895
 :@0.884977:0.970453:0.890322:0.970453:0.890322:0.952432:0.884977:0.952432:0.005345
Foreword by the Vice Chancellor of Universiti Sains :@0.242066:0.104825:0.832253:0.104825:0.832253:0.086058:0.242066:0.086058:0.014543:0.014543:0.009259:0.013234:0.018519:0.014424:0.009259:0.014543:0.006617:0.014543:0.013044:0.006617:0.007926:0.014543:0.013234:0.006617:0.015781:0.006617:0.013234:0.013234:0.006546:0.017185:0.014448:0.013234:0.014543:0.013234:0.013234:0.006617:0.006617:0.014543:0.009259:0.006498:0.014543:0.007926:0.006497:0.017114:0.014543:0.006617:0.013234:0.013234:0.009259:0.013234:0.006617:0.007926:0.006617:0.006498:0.015876:0.013234:0.006522:0.014543:0.013234:0.006617
Malaysia :@0.242066:0.125687:0.347742:0.125687:0.347742:0.106920:0.242066:0.106920:0.019828:0.013234:0.006617:0.013234:0.013234:0.013234:0.006617:0.013060:0.006617
 :@0.906214:0.115206:0.912832:0.115206:0.912832:0.096439:0.906214:0.096439:0.006617
Opening Remarks by Director of INFORMM :@0.242066:0.152429:0.733195:0.152429:0.733195:0.133662:0.242066:0.133662:0.018519:0.014543:0.013234:0.014543:0.006617:0.014543:0.014543:0.006355:0.017185:0.013234:0.021161:0.013234:0.009164:0.013234:0.013234:0.006617:0.014543:0.013234:0.006617:0.017185:0.006617:0.009069:0.013234:0.013234:0.007998:0.014543:0.009259:0.006617:0.014329:0.007926:0.006617:0.006617:0.017185:0.014401:0.018519:0.017185:0.019828:0.019787:0.006617
 :@0.906214:0.152429:0.912832:0.152429:0.912832:0.133662:0.906214:0.133662:0.006617
Welcome Note by Conference Chair :@0.242066:0.179138:0.651239:0.179138:0.651239:0.160371:0.242066:0.160371:0.022470:0.013234:0.006617:0.013234:0.014424:0.021208:0.013234:0.006427:0.017185:0.014448:0.007926:0.013282:0.006617:0.014543:0.013234:0.006522:0.017114:0.014543:0.014543:0.007831:0.013234:0.009140:0.013234:0.014543:0.013234:0.013234:0.006617:0.017090:0.014543:0.013234:0.006617:0.009192:0.006617
 :@0.906214:0.179138:0.912832:0.179138:0.912832:0.160371:0.906214:0.160371:0.006617
Conference Agenda :@0.242066:0.205846:0.473027:0.205846:0.473027:0.187079:0.242066:0.187079:0.017185:0.014543:0.014448:0.007926:0.013282:0.009259:0.013115:0.014543:0.013234:0.013234:0.006450:0.017185:0.014543:0.013282:0.014401:0.014543:0.013167:0.006617
 :@0.906214:0.205846:0.912832:0.205846:0.912832:0.187079:0.906214:0.187079:0.006617
Keynote Abstract :@0.242066:0.233663:0.445376:0.233663:0.445376:0.214896:0.242066:0.214896:0.017185:0.013282:0.013234:0.014424:0.014543:0.007926:0.013234:0.006474:0.017185:0.014543:0.013234:0.007926:0.009259:0.013234:0.013139:0.007866:0.006617
Enhancement of Biosensors Through Biomarkers, Sampling :@0.242066:0.261379:0.879860:0.261379:0.879860:0.242612:0.242066:0.242612:0.015876:0.013234:0.013234:0.013234:0.013115:0.011901:0.013306:0.019661:0.013234:0.013139:0.006617:0.006498:0.013234:0.006617:0.006522:0.015876:0.005284:0.013234:0.011901:0.013234:0.013234:0.012020:0.013115:0.007831:0.011901:0.006617:0.014543:0.013234:0.007926:0.013234:0.013234:0.013092:0.013234:0.006617:0.015781:0.005284:0.013234:0.019828:0.013234:0.007926:0.011901:0.013115:0.007926:0.011997:0.006617:0.006498:0.015876:0.013068:0.019828:0.013234:0.005284:0.005284:0.013234:0.013234:0.006617
and Design:@0.242066:0.282242:0.362317:0.282242:0.362317:0.263475:0.242066:0.263475:0.013234:0.013234:0.013234:0.006617:0.017114:0.013234:0.011973:0.005141:0.013234:0.013234
 :@0.362220:0.282242:0.368837:0.282242:0.368837:0.263475:0.362220:0.263475:0.006617
 :@0.906214:0.271861:0.912832:0.271861:0.912832:0.253094:0.906214:0.253094:0.006617
“From Bench to Bedside to Business” – Translating Research :@0.242066:0.309756:0.894325:0.309756:0.894325:0.290990:0.242066:0.290990:0.007926:0.014543:0.007926:0.013234:0.019828:0.006522:0.015876:0.013234:0.013068:0.011901:0.013306:0.006403:0.006617:0.013234:0.006522:0.015876:0.013234:0.013234:0.011901:0.005284:0.013234:0.013306:0.006617:0.006498:0.013234:0.006427:0.015876:0.013234:0.011901:0.005284:0.013234:0.013163:0.011901:0.011901:0.007926:0.006721:0.013255:0.006556:0.014401:0.007926:0.013282:0.013115:0.011901:0.005284:0.013282:0.006617:0.005284:0.013234:0.013234:0.006379:0.017185:0.013234:0.011901:0.013234:0.013139:0.007926:0.011901:0.013234:0.006617
into Impact: A Personal Experience in Singapore :@0.242066:0.329107:0.759848:0.329107:0.759848:0.310340:0.242066:0.310340:0.005284:0.013234:0.006617:0.013234:0.006522:0.006617:0.019756:0.013234:0.013234:0.011997:0.006617:0.006498:0.006617:0.015757:0.006617:0.015757:0.013234:0.007974:0.011901:0.013234:0.013234:0.013234:0.005284:0.006546:0.015876:0.011782:0.013234:0.013234:0.007998:0.005284:0.013092:0.013234:0.011901:0.013234:0.006522:0.005284:0.013234:0.006617:0.015781:0.005284:0.013234:0.013234:0.013234:0.013234:0.013234:0.007926:0.013235:0.006617
 :@0.906214:0.318323:0.912832:0.318323:0.912832:0.299556:0.906214:0.299556:0.006617
Plenary Abstract :@0.242066:0.363475:0.437537:0.363475:0.437537:0.344709:0.242066:0.344709:0.015876:0.006498:0.013234:0.014543:0.013234:0.009259:0.013234:0.006617:0.017185:0.014448:0.013234:0.007926:0.009259:0.013234:0.013234:0.007834:0.006617
The  Malaysian  Vascular  Events  Risk  (MAVERIK)  Study  – :@0.242066:0.400162:0.894730:0.400162:0.894730:0.381395:0.242066:0.381395:0.014543:0.013234:0.013234:0.006617:0.006212:0.019828:0.013234:0.005284:0.013115:0.011901:0.011901:0.005141:0.013234:0.013234:0.006617:0.006236:0.015876:0.013234:0.011806:0.011901:0.013306:0.005284:0.013092:0.007926:0.006617:0.006093:0.015876:0.011901:0.013234:0.013234:0.006617:0.011901:0.006617:0.006117:0.017185:0.005284:0.011901:0.011901:0.006617:0.006093:0.007926:0.019828:0.015876:0.015876:0.015757:0.017185:0.006617:0.015876:0.007926:0.006617:0.006046:0.015876:0.006498:0.013234:0.013234:0.011997:0.006617:0.006471:0.013398:0.006617
Discovering Biomarkers for Myocardiac Infarction:@0.242066:0.419445:0.759513:0.419445:0.759513:0.400678:0.242066:0.400678:0.017185:0.005284:0.011901:0.011901:0.013234:0.011901:0.013115:0.007926:0.005284:0.013234:0.013306:0.006403:0.015876:0.005284:0.013234:0.019828:0.013234:0.007807:0.011901:0.013234:0.007926:0.011949:0.006617:0.006355:0.013234:0.007974:0.006617:0.019756:0.011901:0.013234:0.011782:0.013234:0.007974:0.013234:0.005141:0.013115:0.011901:0.006617:0.006617:0.013234:0.006522:0.013234:0.007926:0.011901:0.006617:0.005284:0.013234:0.013234
 :@0.759502:0.419445:0.766119:0.419445:0.766119:0.400678:0.759502:0.400678:0.006617
 :@0.906214:0.408661:0.912832:0.408661:0.912832:0.389894:0.906214:0.389894:0.006617
Therapeutic  potentials  of  modified  heparin  derivatives :@0.242066:0.445650:0.894695:0.445650:0.894695:0.426883:0.242066:0.426883:0.014543:0.013234:0.013234:0.007926:0.013234:0.013234:0.013115:0.013234:0.006617:0.005284:0.011782:0.006617:0.016590:0.013234:0.013234:0.006617:0.013234:0.013234:0.006617:0.005284:0.013234:0.005284:0.011782:0.006617:0.016590:0.013234:0.006617:0.006617:0.016543:0.019828:0.013234:0.013234:0.005284:0.006617:0.005284:0.013234:0.013234:0.006617:0.016567:0.013234:0.013234:0.013234:0.013234:0.007926:0.005284:0.013234:0.006617:0.016644:0.013234:0.013234:0.007998:0.005141:0.011901:0.013306:0.006617:0.005284:0.011759:0.013234:0.011901:0.006617
Biosensor for Infectious Diseases :@0.242066:0.464900:0.601211:0.464900:0.601211:0.446133:0.242066:0.446133:0.015876:0.005284:0.013234:0.011901:0.013234:0.013163:0.011901:0.013234:0.007926:0.006617:0.006498:0.013234:0.007926:0.006498:0.006617:0.013234:0.006522:0.013234:0.011973:0.006617:0.005284:0.013234:0.013234:0.011901:0.006450:0.017185:0.005189:0.011901:0.013306:0.013115:0.011901:0.013234:0.011863:0.006617
 :@0.906214:0.454116:0.912832:0.454116:0.912832:0.435349:0.906214:0.435349:0.006617
How to Successfully Register Your Medical Device with MDA :@0.242066:0.490197:0.889119:0.490197:0.889119:0.471430:0.242066:0.471430:0.017185:0.013234:0.017185:0.006617:0.006498:0.013234:0.006617:0.015781:0.013234:0.011973:0.011901:0.013234:0.011782:0.011901:0.006617:0.013234:0.005284:0.005284:0.011949:0.006403:0.017185:0.013282:0.013234:0.005141:0.011901:0.006617:0.013234:0.007998:0.006617:0.015757:0.013234:0.013139:0.007926:0.006617:0.019828:0.013092:0.013234:0.005284:0.011949:0.013234:0.005284:0.006427:0.017185:0.013234:0.011901:0.005284:0.011901:0.013234:0.006498:0.017185:0.005284:0.006617:0.013234:0.006617:0.019828:0.017185:0.015876:0.006617
Malaysia:@0.242066:0.510959:0.335968:0.510959:0.335968:0.492192:0.242066:0.492192:0.019828:0.013234:0.005284:0.013234:0.011901:0.011901:0.005284:0.013234
 :@0.335851:0.510959:0.342469:0.510959:0.342469:0.492192:0.335851:0.492192:0.006617
 :@0.906214:0.500578:0.912832:0.500578:0.912832:0.481811:0.906214:0.481811:0.006617
Molecular and cellular pathology of hereditary neurological :@0.242066:0.537768:0.862889:0.537768:0.862889:0.519001:0.242066:0.519001:0.019828:0.013234:0.005284:0.013234:0.011901:0.013234:0.005284:0.013068:0.007926:0.006617:0.013234:0.013139:0.013234:0.006617:0.011901:0.013234:0.005284:0.005284:0.013234:0.005189:0.013234:0.007974:0.006617:0.013234:0.013234:0.006403:0.013234:0.013234:0.005284:0.013234:0.013234:0.011901:0.006617:0.013234:0.006522:0.006617:0.013234:0.013234:0.007831:0.013234:0.013234:0.005284:0.006617:0.013234:0.007831:0.011901:0.006617:0.013234:0.013234:0.013234:0.007926:0.013234:0.005141:0.013234:0.013234:0.005284:0.011901:0.013234:0.005284:0.006617
and neuropsychiatric disorders:@0.242066:0.558530:0.565545:0.558530:0.565545:0.539763:0.242066:0.539763:0.013234:0.013234:0.013234:0.006617:0.013234:0.013139:0.013234:0.007974:0.013115:0.013234:0.011901:0.011782:0.011901:0.013306:0.005284:0.013234:0.006617:0.007926:0.005141:0.011901:0.006617:0.013234:0.005165:0.011901:0.013234:0.007783:0.013234:0.013234:0.007926:0.011901
 :@0.565517:0.558530:0.572134:0.558530:0.572134:0.539763:0.565517:0.539763:0.006617
 :@0.906214:0.548149:0.912832:0.548149:0.912832:0.529382:0.906214:0.529382:0.006617
Oral Presenter: Diagnostics & Biomarker Discovery :@0.242066:0.589270:0.829831:0.589270:0.829831:0.570503:0.242066:0.570503:0.018519:0.009259:0.013234:0.006617:0.006522:0.015876:0.009259:0.013234:0.013234:0.013234:0.014401:0.007831:0.013234:0.009259:0.007974:0.006617:0.017185:0.006617:0.013044:0.014543:0.014543:0.014543:0.013092:0.007926:0.006617:0.013234:0.013234:0.006617:0.017185:0.006617:0.017185:0.006617:0.014543:0.021065:0.013234:0.009140:0.013234:0.013234:0.009259:0.006617:0.017185:0.006617:0.013234:0.013115:0.014543:0.013234:0.013234:0.009164:0.013381:0.006617
OD1  Quality Assessment of Plain Chest X-Rays of the :@0.242066:0.617591:0.836484:0.617591:0.836484:0.598824:0.242066:0.598824:0.018519:0.017185:0.013184:0.006617:0.017328:0.018519:0.013234:0.013234:0.005284:0.005284:0.006617:0.011901:0.006617:0.015662:0.011901:0.012020:0.013115:0.011901:0.011901:0.019828:0.013234:0.013234:0.006617:0.006522:0.013234:0.006617:0.006522:0.015876:0.005284:0.013234:0.005094:0.013234:0.006617:0.017185:0.013234:0.013163:0.011901:0.006617:0.006617:0.015817:0.007982:0.017114:0.013115:0.011901:0.012020:0.006617:0.013234:0.006522:0.006617:0.006498:0.013234:0.013234:0.006617
Expatriates in Jordan: Multi-Centres Study :@0.314899:0.638454:0.766547:0.638454:0.766547:0.619687:0.314899:0.619687:0.015876:0.011901:0.013234:0.013234:0.006617:0.007926:0.005189:0.013234:0.006617:0.013234:0.011901:0.006617:0.005284:0.013092:0.006617:0.011901:0.013234:0.007998:0.013115:0.013234:0.013234:0.006617:0.006546:0.019828:0.013234:0.005284:0.006617:0.005116:0.007982:0.017185:0.013234:0.013234:0.006522:0.007926:0.013234:0.011901:0.006617:0.015757:0.006617:0.013234:0.013234:0.011815:0.006617
 :@0.906214:0.617591:0.912832:0.617591:0.912832:0.598824:0.906214:0.598824:0.006617
OD2  The Role of Mitogen-Activated Protein Kinases and :@0.242066:0.665162:0.855715:0.665162:0.855715:0.646395:0.242066:0.646395:0.018519:0.017185:0.013184:0.006617:0.012624:0.014543:0.013234:0.013234:0.006617:0.017185:0.013234:0.005189:0.013234:0.006617:0.013234:0.006546:0.006617:0.019756:0.005284:0.006617:0.013234:0.013234:0.013234:0.013139:0.007982:0.015876:0.011901:0.006617:0.005284:0.011782:0.013234:0.006617:0.013234:0.013234:0.006617:0.015757:0.007926:0.013282:0.006617:0.013234:0.005284:0.013234:0.006379:0.015876:0.005284:0.013234:0.013234:0.011901:0.013163:0.011901:0.006617:0.013234:0.013139:0.013234:0.006617
Endoplasmic Reticulum Stress Signaling Pathways in :@0.310196:0.686058:0.877915:0.686058:0.877915:0.667291:0.310196:0.667291:0.015876:0.013234:0.013234:0.013234:0.013234:0.005284:0.013139:0.011901:0.019828:0.005189:0.011901:0.006474:0.017185:0.013282:0.006617:0.005284:0.011759:0.013234:0.005284:0.013234:0.019828:0.006617:0.015781:0.006617:0.007783:0.013234:0.011901:0.011901:0.006617:0.015781:0.005284:0.013234:0.013234:0.013234:0.005284:0.005284:0.013139:0.013115:0.006617:0.015757:0.013234:0.006617:0.013234:0.017185:0.013234:0.011901:0.011901:0.006617:0.005284:0.013234:0.006617
Annatto Tocotrienol-Induced Human Chondrosarcoma :@0.310196:0.706921:0.887350:0.706921:0.887350:0.688154:0.310196:0.688154:0.015876:0.013234:0.013234:0.013234:0.006617:0.006498:0.013234:0.006617:0.014543:0.013234:0.011806:0.013115:0.006617:0.007926:0.005284:0.013234:0.013234:0.013234:0.005229:0.007982:0.006617:0.013234:0.013234:0.013092:0.011901:0.013234:0.013234:0.006522:0.017185:0.013282:0.019828:0.013092:0.013234:0.006626:0.017185:0.013234:0.013234:0.013234:0.013234:0.007831:0.013234:0.011901:0.013234:0.007807:0.011901:0.013306:0.019661:0.013234:0.006617
SW1353 Cell Paraptosis :@0.310196:0.727784:0.574272:0.727784:0.574272:0.709017:0.310196:0.709017:0.015876:0.022470:0.013234:0.013234:0.013139:0.013234:0.006617:0.017185:0.013234:0.005284:0.005284:0.006427:0.015876:0.013234:0.007926:0.013234:0.013234:0.006617:0.013115:0.011901:0.005213:0.011886:0.006617
 :@0.906214:0.665162:0.912832:0.665162:0.912832:0.646395:0.906214:0.646395:0.006617
OD3  Identification of Alpha-1 Antitrypsin as a Candidate :@0.242066:0.754492:0.853799:0.754492:0.853799:0.735725:0.242066:0.735725:0.018519:0.017185:0.013184:0.006617:0.017328:0.006617:0.013234:0.013234:0.013234:0.006617:0.005284:0.006498:0.005284:0.011901:0.013282:0.006617:0.005284:0.013234:0.013234:0.006379:0.013234:0.006617:0.006522:0.015876:0.005284:0.013234:0.013234:0.013303:0.007982:0.013234:0.006617:0.015781:0.013115:0.006617:0.005284:0.006474:0.007926:0.011997:0.013115:0.011901:0.005284:0.013282:0.006617:0.013234:0.011901:0.006617:0.013234:0.006403:0.017185:0.013282:0.013115:0.013234:0.005284:0.013234:0.013234:0.006617:0.013234:0.006617
Biomarker for Post COVID-19 Syndrome by Two-:@0.314899:0.775355:0.833706:0.775355:0.833706:0.756588:0.314899:0.756588:0.015876:0.005284:0.013234:0.019828:0.013234:0.007807:0.011901:0.013234:0.007926:0.006617:0.006498:0.013234:0.007926:0.006498:0.015876:0.013234:0.011901:0.006617:0.006522:0.017185:0.018519:0.015876:0.006617:0.017104:0.007839:0.013234:0.013234:0.006617:0.015805:0.011901:0.013306:0.013115:0.007926:0.013282:0.019661:0.013115:0.006617:0.013234:0.011901:0.006617:0.014543:0.017066:0.013309:0.007926
Dimensional Electrophoresis Proteomic Analysis :@0.314899:0.796217:0.831114:0.796217:0.831114:0.777451:0.314899:0.777451:0.017185:0.005284:0.019828:0.013234:0.013234:0.011901:0.005284:0.013115:0.013234:0.013234:0.005284:0.006450:0.015876:0.005284:0.013234:0.011901:0.006617:0.007926:0.013139:0.013234:0.013234:0.013163:0.007926:0.013234:0.011901:0.005284:0.011901:0.006617:0.015876:0.007783:0.013234:0.006617:0.013234:0.013234:0.019828:0.005118:0.011901:0.006474:0.015876:0.013234:0.013234:0.005284:0.011901:0.011997:0.005141:0.011882:0.006617
 :@0.906214:0.754492:0.912832:0.754492:0.912832:0.735725:0.906214:0.735725:0.006617
OD4  Temperature-Based Refolding of Recombinant :@0.242066:0.822926:0.812945:0.822926:0.812945:0.804159:0.242066:0.804159:0.018519:0.017185:0.013184:0.006617:0.017328:0.014543:0.013234:0.019828:0.013234:0.013139:0.007926:0.013282:0.006617:0.013044:0.007926:0.013343:0.007839:0.015876:0.013234:0.011901:0.013234:0.013282:0.006403:0.017185:0.013282:0.006617:0.013234:0.005284:0.013068:0.005284:0.013234:0.013234:0.006617:0.013234:0.006617:0.006498:0.017185:0.013234:0.011901:0.013234:0.019709:0.013234:0.005284:0.013234:0.013234:0.013282:0.006617:0.006617
Human Epidermal Growth Factor :@0.314899:0.843789:0.668770:0.843789:0.668770:0.825022:0.314899:0.825022:0.017185:0.013282:0.019828:0.013092:0.013234:0.006617:0.015876:0.013234:0.005284:0.013234:0.013092:0.007926:0.019828:0.013234:0.005284:0.006617:0.018376:0.007926:0.013282:0.017185:0.006617:0.013234:0.006427:0.014543:0.013234:0.011973:0.006617:0.013044:0.007946:0.006617
 :@0.906214:0.822926:0.912832:0.822926:0.912832:0.804159:0.906214:0.804159:0.006617
OD5  Exosomal MicroRNA from Blood Plasma as a :@0.242066:0.870497:0.799475:0.870497:0.799475:0.851730:0.242066:0.851730:0.018519:0.017185:0.013184:0.006617:0.017328:0.015876:0.011901:0.013234:0.011901:0.013234:0.019828:0.013234:0.005284:0.006546:0.019828:0.005118:0.011901:0.008021:0.013115:0.017114:0.017185:0.015876:0.006617:0.006498:0.007926:0.013282:0.019828:0.006403:0.015876:0.005284:0.013234:0.013234:0.013234:0.006617:0.015757:0.005284:0.013234:0.011949:0.019661:0.013234:0.006617:0.013234:0.011901:0.006617:0.013234:0.006617
Predictive Biomarker for Bleeding Manifestations in :@0.314899:0.891360:0.858887:0.891360:0.858887:0.872593:0.314899:0.872593:0.015876:0.007926:0.013234:0.013234:0.005165:0.011901:0.006617:0.005284:0.011901:0.013306:0.006617:0.015757:0.005284:0.013092:0.019828:0.013234:0.007855:0.011901:0.013306:0.007926:0.006617:0.006617:0.013044:0.007926:0.006617:0.015876:0.005284:0.013234:0.013234:0.013234:0.005284:0.013092:0.013234:0.006617:0.019828:0.013234:0.013234:0.005284:0.006379:0.013234:0.011973:0.006617:0.013234:0.006522:0.005284:0.013234:0.013115:0.011901:0.006617:0.005284:0.013234:0.006617
Dengue Fever :@0.314899:0.912122:0.472030:0.912122:0.472030:0.893355:0.314899:0.893355:0.017185:0.013282:0.013115:0.013234:0.013234:0.013234:0.006617:0.014543:0.013115:0.011901:0.013234:0.007816:0.006617
 :@0.906214:0.870497:0.912832:0.870497:0.912832:0.851730:0.906214:0.851730:0.006617